Essay on Biotechnology Organization: Motif Bio

This essay will discuss the mission statement of Motif Bio, a clinical-stage biopharmaceutical company that serves as a researcher and manufacturer of antibiotic drugs that combat multi-drug resistant bacteria, as well as the activities of the organization and the role that this organization plays in the U.S. healthcare system.

The mission of Motif Bio is to create novel antibiotics that are effective against infections caused by multi-drug resistant Gram-positive bacteria, such as MRSA. The company’s mission is especially timely, given the rapid increase in multi-drug resistant bacteria cases such as MRSA due to an increase in the misuse of antibiotics, and a growth in the complexity of the bacterial mutation environment. (Motif Bio, 2015)

The organization’s main activities are in research and development, clinical trials, production, distribution, certification, branding and talent recruitment. Foremost, the company invests heavily in research and development, especially through its lead product candidate of iclaprim, for uses such as acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia (HABP), and ventilor associated bacterial pneumonia (VABP). (Motif Bio, 2019) The company then conducts clinical trials to ensure these products are safe for administration to patients in situations such as bacterial infections and knee surgeries. For example, to date, the company has conducted trials on nearly 1,500 patients and healthy volunteers to assess the overall effectiveness and side-effects of iclaprim, its main drug candidate. These trials include REVIVE-1, REVIVE-2 and INSPIRE trials, which are trials for ABSSSI, HABP and VABP respectively. The company also produces and distributes these drugs, and is responsible for the safe, efficient and cost-effective production and distribution of their products to stakeholders such as clinics and hospitals. The company also needs to certify its products to ensure that they can be distributed legally, through certification processes such as the Qualified Infectious Disease Product (QIDP) FDA certification. (Motif Bio, 2015) Next, the company has to brand its products properly for widespread public acceptance, through means such as LinkedIn/social media marketing, tradeshow exhibitions and public lectures. Finally, the company is responsible for talent recruitment, in order to ensure that a diverse and capable team comprising clinical researchers, biochemists, bio-engineers and doctors is able to conduct rigorous and effective research to produce novel anti-multi-drug-resistant bacteria drugs, as well as publish research in renowned journals such as Nature to ensure that Motif Bio stays at the forefront of innovative biopharmaceutical research.

The organization plays an important role in the U.S. healthcare system as a biopharmaceutical company, and works with hospitals, healthcare providers and the government . Studies have shown that over 10 million individuals globally are anticipated to die from drug-resistant bacterial infections by 2050, with 23,000 deaths per year in the U.S. at present. (Czaplewski and Piddock, 2018) In response to this worrying trend, Motif Bio has developed novel anti-MRSA antibiotic solutions. This serves a key role in the U.S. healthcare system, by (a) enabling the work of healthcare providers and hospitals, (b) collaborating with hospitals to ensure safe and efficient drug trials, and (c) working within the government’s support schemes and regulatory frameworks to ensure regulatory compliance. Foremost, Motif Bio enables the work of healthcare providers and hospitals by providing novel antibiotic solutions to combat the scourge of multi-drug resistant bacteria. (Wright, 2007) This has the effect of enabling them to save lives, provide more effective treatment, carry out high infection risk procedures such as surgeries, and save costs on multi-drug resistant antibacterial infections. Secondly, Motif Bio works with hospitals to conduct safe and efficient drug trials on consenting patients. Finally, the government supports Motif Bio’s work through accomodative regulatory frameworks and financial subsidies.

In conclusion, Motif Bio, like other innovative pharmaceutical companies, plays an important role in the U.S. healthcare system through its work on researching and producing novel antibiotic solutions to multi-drug resistant bacteria.

References

Jackson, N., Czaplewski, L., & Piddock, L. J. (2018). Discovery and development of new antibacterial drugs: learning from experience?. Journal of Antimicrobial Chemotherapy, 73(6), 1452-1459.

Motif Bio. (2015). Phase 3 study to evaluate safety and efficacy of iclaprim versus vancomycin for ABSSSI: REVIVE-2 (REVIVE-2). ClinicalTrials. gov identifier NCT02600611. https://clinicaltrials. gov/ct2/show/NCT02600611.

Motif Bio. (2018, January 30). About Motif Bio. Retrieved 2019, April 17 from https://www.motifbio.com/about/

Schneider, P., Hawser, S., & Islam, K. (2003). Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorganic & medicinal chemistry letters, 13(23), 4217-4221.

Wright, G. D., & Sutherland, A. D. (2007). New strategies for combating multidrug-resistant bacteria. Trends in molecular medicine, 13(6), 260-267.